ONCOLOGY Staff

Brad S. Kahl, MD, and Tycel Phillips, MD, discussed the use of acalabrutinib plus bendamustine and rituximab for patients with untreated MCL.

An unusual patient case was presented during a Frontline Forum where experts worked through how to appropriately treat a patient who was having consistent fevers and pain.

During the 2024 IMS Annual Meeting, colleagues gathered to discuss the latest advancements in multiple myeloma.

In a From All Angles program, a patient and her treating physician spoke about the initial diagnosis, care coordination, communication, and the adverse effects observed.

Joshua K. Sabari, MD, and Sandip P. Patel, MD, discussed long-term findings from the phase 3 MARIPOSA trial.

The Oncology Brothers spoke with Benjamin P. Levy, MD, regarding treatment updates for patients with NSCLC with HER2 expression.

During the 2024 IMS conference, teams from Cleveland, Ohio, and New York, New York, met to debate the latest advances in multiple myeloma.

The program was brought together to discuss immunotherapy options for non–clear cell RCC in light of emerging clinical trial data and NCCN guidelines.

Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.

John Marshall, MD, discussed zolbetuximab, which the FDA recently approved for patients with CLDN18.2–positive locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.

Experts in multiple myeloma discussed real-world efficacy and safety data associated with the use of GPRC5D-targeting bispecific agents to treat patients with R/R multiple myeloma.

Clinicians focused on CLL, follicular lymphoma, and MCL gathered during a Frontline Forum to discuss the use of BTKi in each respective disease state.

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

HER-directed treatment approaches in the tumor-agnostic field were the highlight of the discussion for a panel of experts who convened at WCLC 2024.

A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.

Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC.

A panel of experts focused on the use of dual immunotherapy options for patients with metastatic NSCLC without driver mutations.

Experts in non–small cell lung cancer met to debate the latest advances and treatment options and the hottest topics in the space.

The University of Chicago goes against Northwestern Medicine to see who will be crowned the winner in the NSCLC debate.

Experts discussed the advancements in non–small cell lung cancer treatment and developments in both antibody-drug conjugate–based approaches and targeted therapies.

Experts spoke about the best practices for mitigating adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.

Experts in multiple myeloma discussed optimal dosing strategies for bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.

Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.

Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.

Findings from the phase 3 MARIPOSA-2 trial were the subject of a recent discussion of ambivantamab plus chemotherapy with or without lazertinib in EGFR-mutated NSCLC.